Glycoprotein IIb/IIIa receptor

Glycoprotein IIb/IIIa (gpIIb/IIIa, also known as integrin αIIbβ3) is an integrin complex found on platelets.

It is a receptor for fibrinogen and aids in platelet activation.

The complex is formed via calcium-dependent association of gpIIb and gpIIIa, a required step in normal platelet aggregation and endothelial adherence.

Platelet activation by ADP (blocked by clopidogrel) leads to a conformational change in platelet gpIIb/IIIa receptors that induces binding to fibrinogen.

The gpIIb/IIIa receptor is a target of several drugs.

Defects in glycoprotein IIb/IIIa cause Glanzmann’s thrombasthenia.

Autoantibodies against IIb/IIIa can be produced in immune thrombocytopenic purpura.

Glycoprotein IIb/IIIa inhibitors can be used to prevent blood clots in an effort to decrease the risk of heart attack or stroke.

A platelet surface receptor that plays a key role in formation of a platelet rich thrombus by combining with fibrinogen and other ligands.

Is the primary platelet receptor of fibrinogen.

Several GpIIb/IIIa inhibitors exist: abciximab (ReoPro), eptifibatide (Integrilin) and tirofiban (Aggrastat).

Glycoprotein IIb/IIIa inhibitors are frequently used during percutaneous coronary interventions, presenting platelet aggregation and clot formation.

Glycoprotein IIb/IIIa inhibitors may also be used to treat acute coronary syndromes.

Glycoprotein IIb/IIIa inhibitors are given intravenously.

Leave a Reply

Your email address will not be published. Required fields are marked *